IL6 and atherosclerosis: Increased plasma IL-6 levels correlates with risk for CAD (41–43), furthermore treatment of patients with high atherosclerotic risk with ziltivekimab, a human monoclonal antibody against IL-6, resulted in a reduction of inflammation biomarkers relevant to atherosclerosis (44).